ADOCIA

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions

in the field of metabolic diseases, primarily diabetes and obesity.

The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1)

The BioChaperone® technology for the development of new generation insulins and products combining

insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an

immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells

transplantation; 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has more than 80 employees.

Adocia is listed on the regulated market of EuronextTM Paris (Euronext: ADOC; ISIN: FR0011184241).